传承精华，守正创新。此次活动的成功举办，不仅是向医圣先贤的致敬，更是对中医药未来发展的 积极谋划。它标志着仲景学术的传承与应用进入了协同发力、融合创新的新阶段，将为中医药事业的繁 荣发展书写新的华章。 （责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 为提升基层医疗服务能力，推动专病防治水平，大会举行了"不孕不育生殖健康巡讲专家行"和"结 节及肿瘤防治巡讲专家行"专家聘书颁发仪式、《仲景全书》现场授书仪式等活动。 好医生药业集团副总经理、沈阳清宫药业集团有限公司总经理刘汉军在大会总结中表示，通过此次 活动，加深了对中医药文化的理解，对中医中药的未来充满了期待。 9月22日，由中国医药教育协会主办，中国医药教育协会新中医发展促进专业委员会、医圣文化 园、好医生药业集团、清宫药业集团共同承办的"第二届仲景学术传承与应用学术大会及医圣仲景祭拜 大典"在河南南阳召开。大会以"传承仲景学术，弘扬 ...

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. reported a net profit of 522.34 million yuan for the first half of 2025, reflecting a year-on-year increase of 5.80% despite a decline in revenue [2][3][9] Financial Performance - Total revenue for the first half of 2025 was 2.14 billion yuan, down 5.79% from the previous year [2][3] - The total profit for the period was 703.24 million yuan, an increase of 12.01% compared to the same period last year [2][3] - The company's net assets reached 3.95 billion yuan, up 2.15% year-on-year [3] Business Segments - The OTC (over-the-counter) segment saw a revenue decline of 10.14%, attributed to changes in terminal demand [14] - The health consumer products segment achieved a revenue growth of 17.35%, focusing on self-researched products [14] - The prescription drug segment reported a revenue increase of 7.44%, emphasizing compliance and academic marketing [15] Industry Context - The pharmaceutical manufacturing industry experienced a PPI decline of 1.5% in the first half of 2025, with total revenue down 1.2% year-on-year [4][5] - National policies are aimed at enhancing medical insurance coverage and promoting high-quality development in the pharmaceutical sector [5][6] - The government is focusing on the development of traditional Chinese medicine, with initiatives to improve quality and promote innovation [8] Strategic Initiatives - The company is committed to brand-driven and innovation-driven growth, with plans to enhance its product matrix in key categories [18] - Jiangzhong Pharmaceutical is actively pursuing mergers and acquisitions to expand its product offerings and market presence [18] - The company is investing in digital transformation and smart manufacturing to improve operational efficiency and product quality [16][17]

Core Viewpoint - The article highlights the transformation of Kunming Pharmaceutical Group's subsidiary, Kunzhongyao 1381, from a traditional pharmacy established in 1381 to a modern enterprise that embodies the unique value of traditional Chinese medicine in the context of an aging population [1][6]. Group 1: Heritage and Tradition - Kunzhongyao 1381 has a 600-year history that reflects the evolution from a local pharmacy to a national-level intangible cultural heritage enterprise, showcasing the enduring significance of traditional Chinese medicine [1][2]. - The company relies on the "Dian Nan Ben Cao," a significant pharmacological text, as a foundational reference for product development, documenting the use of 458 local medicinal materials [2]. - The traditional preparation methods of Chinese medicine, recognized as a national intangible cultural heritage, are preserved and integrated into the production processes, ensuring the quality and efficacy of their products [2]. Group 2: Innovation and Modernization - The company is adapting ancient wisdom to meet contemporary health needs, focusing on the emotional well-being of the elderly by modernizing classic formulas like Xiaoyao San into products such as Shugan Granules [3]. - Kunzhongyao has established a standardized planting base across multiple provinces, ensuring a reliable supply of authentic medicinal materials, which supports the preservation of traditional preparation techniques [3]. Group 3: Brand Strategy and Market Positioning - At the 2025 Health Industry Conference, Kunzhongyao 1381 announced a new brand positioning aimed at upgrading its brand and innovating its product line, emphasizing the integration of cultural heritage with high-quality Chinese medicine [4]. - The company is strategically positioned as a leader in the silver economy, aligning its offerings with the growing demand for chronic disease management and health maintenance among the elderly [6]. Group 4: Future Outlook - The Chinese government's policies promoting the use of traditional medicine in elder care create opportunities for Kunzhongyao to deepen its involvement in the silver economy [6]. - The company plans to leverage its century-old brand influence through a three-phase development strategy, focusing on establishing brand recognition, expanding high-quality product offerings, and promoting its brand globally [6].

Core Insights - Hong Kong Guangren Tang Pharmaceutical Co., Ltd. has a rich history dating back to 1903, showcasing a commitment to traditional Chinese medicine while embracing innovation [2][10] - The company was founded by Liu Nan Gong, who transitioned from a scholar to a physician in response to the health crises of his time, establishing a legacy of compassionate care [2][3] - The company has evolved from a small clinic to a significant player in the industry, maintaining its core values of quality and community service [6][10] Company History - The establishment of Guangren Tang in 1903 marked a pivotal moment, with Liu Nan Gong dedicating his life to medicine after witnessing the suffering caused by epidemics [2][3] - The initial setup included two consultation rooms and a pharmacy, emphasizing a charitable approach to healthcare by providing free services to the needy [3][4] - Liu Nan Gong's innovative "Three Discrimination Therapy" became well-known for effectively treating various ailments, enhancing his reputation in the community [2][4] Leadership and Development - In 1908, Liu Nan Gong's son, Ji Men, took over the leadership, focusing on preserving and documenting his father's medical practices, resulting in the compilation of "Guangren Tang Medical Treatises" [4][5] - Ji Men established a quality control system for medicinal herbs, ensuring the efficacy of treatments, and developed the "Children's Tranquil Powder," which gained popularity for treating pediatric conditions [5][6] - Under Ji Men’s management, Guangren Tang expanded its operations, producing various traditional Chinese medicines and laying the groundwork for the future establishment of Hong Kong Guangren Tang Pharmaceutical Co., Ltd. in the 1950s [6][10] Modernization and Innovation - The company embraced modernization in the 1970s under the leadership of Liu Mu Xian, incorporating modern pharmaceutical equipment while preserving traditional methods [7][8] - The development of "Guangren Huoluo Pills" became a flagship product, addressing common health issues among office workers and achieving significant market success [8][10] - In the 21st century, the company has focused on integrating traditional practices with modern scientific research, collaborating with universities to validate the efficacy of its products [9][10] Quality Control and Market Expansion - The company has established a comprehensive quality control system, including 12 medicinal herb cultivation bases, ensuring high standards from cultivation to production [9] - Products have gained international recognition, successfully entering European markets after passing stringent regulatory processes [9] - The company actively engages in community service and cultural preservation, contributing 5% of its revenue to traditional Chinese medicine initiatives and establishing scholarships for students in the field [9][10]

Core Insights - The Qingdao Traditional Chinese Medicine (TCM) Inheritance and Innovation Base project has successfully passed its completion inspection, showcasing a modern park dedicated to the mission of TCM inheritance and innovation [1] Group 1: Project Overview - The first phase of the Qingdao TCM Inheritance and Innovation Base project covers approximately 150 acres with a total construction area of about 150,000 square meters, consisting of 14 individual buildings that include various functional areas such as laboratories, research incubation buildings, and wellness centers [3] - The project is divided into two main sections: the west area focuses on research and incubation with a design inspired by Tai Chi and traditional Chinese elements, while the east area emphasizes medical and wellness services, incorporating classical garden design and traditional courtyard structures [3] Group 2: Facilities and Features - The experimental building A is spacious and well-lit, featuring areas for the cultivation and exhibition of traditional Chinese medicinal plants, as well as pilot workshops and animal laboratories for innovative experiments [5] - The research incubation building spans approximately 7,700 square meters and includes meeting rooms, offices, and a 400-person auditorium, while the research support building offers dining, conference, and accommodation facilities with a total area of about 20,000 square meters [7] - The wellness building provides a comfortable living environment with 116 wellness apartments and 162 beds for elderly care, along with transitional medical service areas for patients [7] Group 3: Collaboration and Future Plans - The project will collaborate with Shandong University of Traditional Chinese Medicine to establish a hospital that leverages expert resources to provide TCM diagnosis and treatment services for complex diseases, as well as preventive care and wellness services [9] - As a key construction project in Qingdao High-tech Zone, the TCM base aims to become a highland for marine TCM research and an innovation hub, integrating technology innovation, talent cultivation, and industry incubation to enhance TCM and wellness services for the local community [9]